Brian Viscount
About Brian Viscount
Brian Viscount serves as the Vice President of Biopharma and DNA Production at Applied DNA Sciences, where he has worked since 2021. He has extensive experience in product management and development, having held various leadership roles at companies such as Stratix Corporation and Symbol Technologies Inc.
Current Role at Applied DNA Sciences
Brian Viscount serves as the Vice President of Biopharma and DNA Production at Applied DNA Sciences since 2021. In this role, he oversees the development and production of DNA-based solutions aimed at addressing various biopharmaceutical needs. His leadership contributes to the company's mission of advancing DNA technology for applications in health and safety.
Previous Experience at Applied DNA Sciences
Prior to his current position, Brian Viscount held multiple roles at Applied DNA Sciences. He served as Executive Director from 2018 to 2021, and as Director of Product Management from 2015 to 2021. His tenure involved significant contributions to product strategy and management, enhancing the company's offerings in DNA technology.
Work History at Symbol Technologies Inc.
Brian Viscount spent a substantial part of his career at Symbol Technologies Inc., where he held various positions from 1987 to 2002. His roles included Custom Products Engineering, Product Manager for the Scanning Products Division, Senior Director of Product Marketing, and Vice President of Product Management. His experience at Symbol Technologies contributed to his expertise in product management and marketing within the technology sector.
Educational Background
Brian Viscount earned a Master of Business Administration from Long Island University, completing his studies from 1995 to 1997. He also holds a Bachelor of Science degree in Mathematics from SUNY Oneonta, where he studied from 1979 to 1983. His educational background provides a strong foundation for his career in management and technology.
Research and Contributions
Brian Viscount has been involved in significant research initiatives, including leading a COVID-19 linear DNA vaccine trial at Cornell University. He co-authored a manuscript on LinearDNA™ vaccines for cancer immunotherapy and supported the deployment of automated COVID-19 diagnostic solutions at Applied DNA Sciences Clinical Lab and Stony Brook University Hospital. His work in managing COVID-19 testing processes has been crucial during the pandemic.